Linezolida Farmoz (Linezolid)

Linezolida Farmoz is indicated for infections caused by susceptible Gram‑positive bacteria, particularly those resistant to other agents.

• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: effective treatment of skin, soft‑tissue and bloodstream infections.
• Vancomycin‑resistant Enterococcus (VRE) infections: provides an alternative oral option for serious enterococcal disease.
• Skin and soft‑tissue infections caused by Gram‑positive bacteria: resolves cellulitis, abscesses and wound infections.
• Community‑acquired and hospital‑acquired pneumonia: treats pneumonia caused by susceptible organisms.
• Bacteremia and sepsis due to susceptible Gram‑positive pathogens: aids in rapid bacterial clearance.

• Linezolid binds to the 50S subunit of bacterial ribosomes, preventing the formation of the initiation complex required for protein synthesis. By inhibiting the early stage of translation, it halts bacterial growth and leads to bacteriostatic activity against a range of Gram‑positive organisms, including those resistant to other antibiotic classes.

Linezolida Farmoz may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Headache: transient cranial discomfort.
• Diarrhea: loose stools, usually self‑limiting.
• Metallic taste: altered taste perception during therapy.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count requiring monitoring.
• Peripheral neuropathy: nerve damage presenting as tingling or numbness.
• Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents.
• Optic neuritis: inflammation of the optic nerve that may affect vision.

When prescribing Linezolida Farmoz, clinicians should consider several safety measures.

• Renal function assessment: evaluate kidney status and monitor for accumulation in severe impairment.
• Hematologic monitoring: obtain baseline and periodic complete blood counts due to risk of thrombocytopenia and anemia.
• Serotonergic drug interaction: avoid concurrent use with SSRIs, SNRIs or MAO inhibitors because of serotonin syndrome risk.
• Mitochondrial toxicity: monitor for signs of lactic acidosis during prolonged therapy.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk; data are limited.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Linezolida Farmoz can interact with several drug classes; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: increased risk of serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): additive serotonergic effects.
• Rifampicin: induces metabolism, reducing linezolid plasma concentrations.
• Carbamazepine and other enzyme‑inducing anticonvulsants: may lower exposure and efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: potentiates anticoagulant effect; monitor INR closely.
• Theophylline: possible increased serum levels; watch for toxicity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): combined risk of bleeding when thrombocytopenia occurs.